Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

SFI reported for 2023 by IFRS

3/28/24 SFIN

Kristall reported for January-February 2024

3/28/24 KLVZ

Gokhran unexpectedly started buying stones from Alrosa

3/28/24 ALRS

Supervisory Board was replenished with new members

3/28/24 X5

Headhunter shareholders approved the redomiciliation

3/27/24 HEAD

ZIL reported for 2023 by RAS

3/27/24 ZILL

SPB Exchange to focus on IPOs of companies under sanctions

3/27/24 SPBE

Lenzoloto reported for 2023 by RAS

3/27/24 LNZL

Belon reported for 2023 according by RAS

3/27/24 BLNG

Moscow Exchange expands the range of OTC share market instruments

3/27/24 MOEX